Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Scott L. Gottlieb, Patricia Gilleaudeau, Ray Johnson, Len Estes, Thasia G. Woodworth, Alice B. Gottlieb, James G. Krueger

Research output: Contribution to journalArticlepeer-review

594 Scopus citations

Abstract

Psoriasis is a hyperproliferative and inflammatory skin disorder of unknown aetiology. A fusion protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB389IL-2), which selectively blocks the growth of activated lymphocytes but not keratinocytes, was administered systemically to ten patients to gauge the contribution of activated T cells to the disease. Four patients showed striking clinical improvement and four moderate improvement, after two cycles of low dose IL-2–toxin. The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3+ and CD8+ T cells, suggesting a primary immunological basis for this widespread disorder.

Original languageEnglish
Pages (from-to)442-447
Number of pages6
JournalNature Medicine
Volume1
Issue number5
DOIs
StatePublished - May 1995
Externally publishedYes

Fingerprint

Dive into the research topics of 'Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis'. Together they form a unique fingerprint.

Cite this